Tumor Induced Dysregulation of T Cell Immunity
肿瘤诱导的 T 细胞免疫失调
基本信息
- 批准号:7094661
- 负责人:
- 金额:$ 27.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-05-12 至 2011-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Mounting evidence suggests that the tumor environment can inhibit the development of an effective immune response by promoting T cell dysfunction. Studies from our laboratory and several others suggest that the ability of tumors and their products to promote T cell death represents an important mechanism of immune dysfunction. Flow cytometry analysis of tumor infiltrating T cells stained with AnnexinV/7AAD as well as in situ TUNEL staining revealed that a high percentage of these cells showed signs of apoptosis/necrosis, suggesting that the tumor microenvironment has a deleterious effect on tumor infiltrating T cells (TILs), although the immunosuppressive effects of RCC extend into the periphery as well. Additional studies demonstrated that in patients with active disease the T cell response to MAGE-6 and EphA2, expressed by renal cell carcinomas was predominately Type-2 (IL-4, IL-5.IL-10) rather than a type-1(IFNg) which is known to be critical for the development of effective anti-tumor immunity. However, patients rendered disease free by surgery displayed Th-1 responses (IFNg, ELISPOT). HLA-DR4/tumor peptide tetramer studies showed that the MAGE-6 and EphA2 specific CD4+T cells were highly sensitive to apoptosis compared to T cells binding influenza peptides and the bulk peripheral blood T cell population. Our data also suggest that gangliosides play in important role in tumor-induced immune dysfunction. Gangliosides constitute over 50% of the apoptotic activity induced by supernatants from RCC explants and by RCC lines. RCC derived gangliosides can also induce a Th2 bias in vitro. HPLC with on line mass spectrometry analysis suggests that there are several gangliosides, including GM2, which mediate the immunosuppression. Here we plan to determine which of the common gangliosides derived from RCC tissue, supernatant and plasma are the most effective at inducing T cell death, a Type-2 bias, and whether the bias is related to the apoptosis of the MAGE-6 and EphA2 specific Th-1 T cells. We will also determine whether the immune suppression is mediated by select gangliosides shedding from tumor and associating with lipid rafts on the plasma membranes of T cells and whether expression of the inhibitory gangliosides correlates with the Th-2 bias and increased sensitivity of patient T cells to apoptosis (aim1). Whether T cell death induced by ganglosides results from degradation to ceramide or to their migration to mitochondria will be examined (aim2). The observation that the anti-oxidant deferoxamine (DFO) can block ganglioside-mediated apoptosis of T cells will be studied further to define how DFO protects T cells from apoptosis. We will also define the sequence of events leading to T cell death, including the role of iron and lysosomes in this process (aim 3)
描述(由申请人提供):越来越多的证据表明,肿瘤环境可以通过促进T细胞功能障碍来抑制有效免疫应答的发展。我们实验室和其他几个实验室的研究表明,肿瘤及其产物促进T细胞死亡的能力是免疫功能障碍的重要机制。用AnnexinV/7AAD染色的肿瘤浸润性T细胞的流式细胞术分析以及原位TUNEL染色揭示了高百分比的这些细胞显示出凋亡/坏死的迹象,表明肿瘤微环境对肿瘤浸润性T细胞(TIL)具有有害作用,尽管RCC的免疫抑制作用也延伸到外周。另外的研究表明,在患有活动性疾病的患者中,对肾细胞癌表达的法师-6和EphA 2的T细胞应答主要是2型(IL-4、IL-5、IL-10)而不是1型(IFNg),已知1型(IFNg)对于有效的抗肿瘤免疫的发展至关重要。然而,通过手术使疾病消失的患者显示Th-1应答(IFNg,ELISPOT)。HLA-DR 4/肿瘤肽四聚体研究显示,与结合流感肽的T细胞和大量外周血T细胞群相比,法师-6和EphA 2特异性CD 4 +T细胞对细胞凋亡高度敏感。我们的数据还表明,神经节苷脂在肿瘤诱导的免疫功能障碍中起重要作用。神经节苷脂占RCC外植体上清液和RCC细胞系诱导的凋亡活性的50%以上。RCC衍生的神经节苷脂还可以在体外诱导Th 2偏好。HPLC和在线质谱分析表明,有几个神经节苷脂,包括GM 2,介导的免疫抑制。在这里,我们计划确定哪种来自RCC组织、上清液和血浆的常见神经节苷脂在诱导T细胞死亡(2型偏倚)方面最有效,以及该偏倚是否与法师-6和EphA 2特异性Th-1 T细胞的凋亡有关。我们还将确定免疫抑制是否是由选择性神经节苷脂从肿瘤脱落介导的,并与T细胞质膜上的脂筏相关,以及抑制性神经节苷脂的表达是否与Th-2偏倚和患者T细胞对凋亡的敏感性增加(aim 1)相关。将检查由神经节苷脂诱导的T细胞死亡是否是由于降解为神经酰胺或其迁移至线粒体所致(aim 2)。抗氧化剂去铁胺(DFO)可以阻断神经节苷脂介导的T细胞凋亡,这一观察结果将进一步研究DFO如何保护T细胞免于凋亡。我们还将定义导致T细胞死亡的事件顺序,包括铁和溶酶体在这一过程中的作用(目的3)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES H FINKE其他文献
JAMES H FINKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES H FINKE', 18)}}的其他基金
Tumor Induced Dysregulation of T Cell Immunity
肿瘤诱导的 T 细胞免疫失调
- 批准号:
7232399 - 财政年份:2006
- 资助金额:
$ 27.94万 - 项目类别:
Tumor Induced Dysregulation of T Cell Immunity
肿瘤诱导的 T 细胞免疫失调
- 批准号:
7422384 - 财政年份:2006
- 资助金额:
$ 27.94万 - 项目类别:
Tumor Induced Dysregulation of T Cell Immunity
肿瘤诱导的 T 细胞免疫失调
- 批准号:
7596879 - 财政年份:2006
- 资助金额:
$ 27.94万 - 项目类别:
Tumor Induced Dysregulation of T Cell Immunity
肿瘤诱导的 T 细胞免疫失调
- 批准号:
7783758 - 财政年份:2006
- 资助金额:
$ 27.94万 - 项目类别:
Ganglioside Regulation of NFkbeta and Apoptosis
神经节苷脂对 NFkbeta 和细胞凋亡的调节
- 批准号:
6321322 - 财政年份:2001
- 资助金额:
$ 27.94万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 27.94万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
- 批准号:
10762827 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:














{{item.name}}会员




